In breve
Clinical trials are studying AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE in people with transfusion-dependent beta-thalassemia. These studies aim to check whether the treatment is safe and effective, especially whether patients can become independent from regular blood transfusions.
Punti chiave
- Clinical trials are studying AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE in transfusion-dependent beta-thalassemia. The provided trial is a Phase 2, single-arm, open-label, multicenter study. It includes pediatric and adult patients, and the main goal is to see whether patients can become independent from red blood cell transfusions. The key outcome measures transfusion independence for at least 12 months and looks at hemoglobin levels over time. The trial is authorised and has an enrollment of 9 participants.
Overview of the clinical research
The available trial is studying AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE in people with transfusion-dependent beta-thalassemia. The brief study goal is to evaluate clinical efficacy in terms of transfusion independence in pediatric and adult patients.
This research is focused on whether the treatment can help patients go without regular red blood cell transfusions. The trial is described as a gene therapy study and is being run as an interventional clinical study.
Study design and phase
The study is a single arm, open label, multicenter, single-dose trial. Single arm means there is no separate comparison group listed in the provided data, and open label means both the study team and participants know what is being given.
The trial is in Phase 2 and has an authorised status. Phase 2 studies usually look more closely at whether a treatment works while continuing to monitor safety, and this matches the trial’s stated aim to evaluate efficacy and safety.
Who can participate
The target population is people with transfusion-dependent beta-thalassemia, including both pediatric and adult patients. The data provided do not list more detailed inclusion or exclusion rules, so only this broad group can be confirmed from the source.
Beta-thalassemia is a blood disorder that affects hemoglobin, the part of red blood cells that carries oxygen. In transfusion-dependent disease, patients need regular transfusions to keep blood levels stable.
What the trials measure
The main endpoint is the proportion of subjects achieving transfusion independence. In this study, transfusion independence means a weighted average hemoglobin of at least 9.0 g/dL without any red blood cell transfusion for a continuous period of at least 12 months.
The assessment of this outcome starts 60 days after the last red blood cell transfusion used for post-transplant support or standard care for beta-thalassemia. This timing helps the researchers judge the effect of the treatment after the transfusion support period has ended.
In simple terms, the trial is asking whether patients can keep a good enough blood level for a full year without needing transfusions. That is why hemoglobin level and transfusion-free time are the key measures in this study.
Trial summary
Only one trial is provided in the source data, and it is a Phase 2, interventional study with 9 planned participants. The study is authorised and is being conducted in a multicenter setting.
The intervention list also includes busulfan, granulocyte colony-stimulating factor product GRANOCYTE, and plerixafor, but the source only lists these as study drugs and does not explain them in detail. The main research question remains whether the gene therapy can reduce or remove the need for transfusions in beta-thalassemia.
Below is a short summary of the trial information from the source data.
| Trial ID | Title | Phase | Condition | Status | Enrollment |
|---|---|---|---|---|---|
| 2025-522160-32-00 | Single-arm, open-label, multicenter, single-dose study of gene therapy using autologous CD34+ hematopoietic stem cells transduced with the GLOBE lentiviral vector | Phase 2 | Transfusion-dependent beta-thalassemia | Authorised | 9 |
Important patient terms
Interventional study means the research team gives a treatment and then measures the results.
Open label means there is no blinding, so everyone knows which treatment is being used.
Multicenter means the study is being done at more than one hospital or research site.
Single-dose means the treatment is given one time as part of the study plan.
Transfusion independence means not needing red blood cell transfusions for a set period while keeping blood levels high enough.